Vaccine specialist Novavax (NASDAQ: NVAX) plans to file for an emergency use authorization with the Food and Drug Administration for its COVID-19 vaccine candidate in July. In addition, the biotech's vaccine candidate for influenza, NanoFlu, is waiting for a green light from the regulator. Last year, a phase 3 study of NanoFlu showed it to be superior to the market-leading flu vaccine from Sanofi (NASDAQ: SNY) in a head-to-head match-up.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting